Generics
US FDA approves Lannett's New Drug Application for Dronabinol Capsules USP, 2.5mg, 5mg and 10mg
22 May 2018 -

The United States Food and Drug Administration (FDA) has approved the Abbreviated New Drug Application for United States-based Lannett Company Inc's (NYSE: LCI) Dronabinol Capsules USP, 2.5mg, 5mg and 10mg, it was reported yesterday.

For the 12 months ended March 2018, total US sales of Dronabinol Capsules USP, 2.5mg, 5mg and 10mg, was around USD120m, according to IMS.

Tim Crew, chief executive officer of Lannett, said, 'The approval of Dronabinol Capsules adds to our sizeable portfolio of near-term product opportunities. We expect to commence marketing several products including Dronabinol Capsules over the course of this year. Currently, only a handful of manufacturers supply generic Dronabinol Capsules to the US market.'

Login
Username:

Password: